NR3C2 and Sjogren syndrome: Cevimeline is a parasympathomimetic and direct-acting MR agonist, usually indicated for treating the symptoms of dry mouth in patients with Sjögren’s syndrome and the therapeutic remedy for treating AD (Oleksak et al., 2021).